Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 100 participants.

Also called NCT05350592

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05350592
  • EudraCT 2021-002028-19
  • WHO UTN U1111-1277-8523
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05350592. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-13 (actual); primary completion 2025-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
Acronym
DOBERMANN
Condition
Acute Myocardial Infarction
Condition
Cardiogenic Shock
Intervention (Drug)
Tocilizumab
Intervention (Drug)
Dobutamine
Intervention (Drug)
NaCl 0.9%
Lead sponsor
Copenhagen University Hospital, Rigshospitalet (class: other)
Collaborator
Novo Nordisk A/S (class: industry)
Collaborator
Simon Spies Fonden (class: not stated)
Collaborator
Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat (class: not stated)

Record details

Record id
cardio:ct-nct05350592
Content hash
a18f5aa94e68d91fe1324179989f9ea77d33c105a9d48e83988f3e22d0f569ce